Agno Pharma, a global pharmaceutical CDMO, acquired Lubrizol Particle Sciences Inc. The acquisition includes the drug product formulation technology behind the Particle Sciences Inc. business as well as the Bethlehem, PA, development, and manufacturing site which employs approximately 65 employees.

Particle Sciences specializes in preclinical and clinical stage drug product formulation and offers a comprehensive suite of supporting services, including analytic, bioanalytic, physical characterization, and manufacturing. The company has expertise in dealing with poorly soluble and highly potent compounds in both sterile and non-sterile environments.

The acquisition of Particle Sciences will provide Agno with expanded capability and capacity to extend its drug product formulation and clinical manufacturing services to its customers globally. Agno plans to further invest in clinical scale manufacturing services from sterile liquid manufacturing and filling services to micronization of sterile powder filling capabilities.